SOPH Stock Forecast & Price Target

Sophia Genetics is well positioned by a compounding, cloud-based SaaS model that analyzes more than 2.5 million genomic profiles across roughly 1,000 institutions in 75 countries, creating a durable data moat that improves algorithms and retention over time. Its recurring, pay-per-analysis revenue model is scaling with rising demand for in-house genomic testing, while 2025 revenue of $77.3M grew 19% YoY and adjusted gross margin reached 74.2%, with FY26 guidance of $94M–$96M and a target of positive adjusted EBITDA in 2H27. The bullish case is further strengthened by accelerating U.S. adoption, high-value partnerships with Memorial Sloan Kettering, MD Anderson, and AstraZeneca, and expanding biopharma and companion-diagnostic applications that should deepen both volumes and margins.

Sophia Genetics is exposed to a weak fundamental setup because future revenue still depends on costly commercial expansion, yet 2024 delivered only 4% revenue growth despite 11% volume growth, implying lower revenue per analysis and softness among biopharma customers. Its platform also faces intense competition from centralized testing providers, analytics platform rivals, and sequencer manufacturers that can bundle competing tools, which could pressure market share and pricing. On top of that, the company is not profitable, may need additional capital through equity issuance, and faces cybersecurity, patent, and litigation risks that could raise costs, dilute shareholders, and disrupt adoption.